Literature DB >> 18801736

The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities.

Eyal Kalie1, Diego A Jaitin, Yulia Podoplelova, Jacob Piehler, Gideon Schreiber.   

Abstract

Type I interferons (IFNs) signal for their diverse biological effects by binding a common receptor on target cells, composed of the two transmembrane IFNAR1 and IFNAR2 proteins. We have previously differentially enhanced the antiproliferative activity of IFN by increasing the weak binding affinity of IFN to IFNAR1. In this study, we further explored the affinity interdependencies between the two receptor subunits and the role of IFNAR1 in differential IFN activity. For this purpose, we generated a panel of mutations targeting the IFNAR2 binding site on the background of the IFNalpha2 YNS mutant, which increases the affinity to IFNAR1 by 60-fold, resulting in IFNAR2-to-IFNAR1 binding affinity ratios ranging from 1000:1 to 1:1000. Both the antiproliferative and antiviral potencies of the interferon mutants clearly correlated to the in situ binding IC(50) values, independently of the relative contributions of the individual receptors, thus relating to the integral lifetime of the complex. However, the antiproliferative potency correlated throughout the entire range of affinities, as well as with prolonged IFNAR1 receptor down-regulation, whereas the antiviral potency reached a maximum at binding affinities equivalent to that of wild-type IFNalpha2. Our data suggest that (i) the specific activity of interferon is related to the ternary complex binding affinity and not to affinity toward individual receptor components and (ii) although the antiviral pathway is strongly dependent on pSTAT1 activity, the cytostatic effect requires additional mechanisms that may involve IFNAR1 down-regulation. This differential interferon response is ultimately mediated through distinct gene expression profiling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18801736     DOI: 10.1074/jbc.M806019200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

Review 1.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

Review 2.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

3.  Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes.

Authors:  Srilalitha Kuruganti; Shane Miersch; Ashlesha Deshpande; Jeffrey A Speir; Bethany D Harris; Jill M Schriewer; R Mark L Buller; Sachdev S Sidhu; Mark R Walter
Journal:  J Biol Chem       Date:  2015-11-06       Impact factor: 5.157

4.  IFN-β-specific signaling via a unique IFNAR1 interaction.

Authors:  Surinder Kaur; Leonidas C Platanias
Journal:  Nat Immunol       Date:  2013-09       Impact factor: 25.606

5.  A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus.

Authors:  Peng Du; Lei Xu; Weiyi Qiu; Dadi Zeng; Junjie Yue; Shuang Wang; Peitang Huang; Zhiwei Sun
Journal:  MAbs       Date:  2015       Impact factor: 5.857

6.  Stochastic receptor expression determines cell fate upon interferon treatment.

Authors:  Doron Levin; Daniel Harari; Gideon Schreiber
Journal:  Mol Cell Biol       Date:  2011-06-20       Impact factor: 4.272

Review 7.  The molecular basis for differential type I interferon signaling.

Authors:  Gideon Schreiber
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

Review 8.  Interferon-stimulated genes: a complex web of host defenses.

Authors:  William M Schneider; Meike Dittmann Chevillotte; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2014-02-06       Impact factor: 28.527

9.  Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.

Authors:  Igor A Kaltashov; Cedric E Bobst; Rinat R Abzalimov; Steven A Berkowitz; Damian Houde
Journal:  J Am Soc Mass Spectrom       Date:  2009-10-29       Impact factor: 3.109

10.  Evaluating annotations of an Agilent expression chip suggests that many features cannot be interpreted.

Authors:  E Michael Gertz; Kundan Sengupta; Michael J Difilippantonio; Thomas Ried; Alejandro A Schäffer
Journal:  BMC Genomics       Date:  2009-11-30       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.